Compare Eaton Corporation plc (ETN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Neurocrine Biosciences Inc — how do they compare? Eaton Corporation plc trades at $428.21 (market cap $164.88B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Eaton Corporation plc is far larger — about 11.5× Neurocrine Biosciences Inc's market cap, and Eaton Corporation plc pays a 1.04% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Neurocrine Biosciences Inc for 23 Days on average.
| ETN | NBIX | |
|---|---|---|
Market Cap | $164.88B | $14.36B |
Volume | 2,535,086 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $459.96 | $185.50 |
52-Week Low | $315.82 | $123.10 |
Typical Hold Time | 31 Days | 23 Days |
Enterprise Value | $185.51B | $14.37B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $431.33, down 3.09% today but maintains strong analyst support with 70% buy ratings. The company shows consistent earnings beats and robust profitability with 12.75% net margins. Technical indicators suggest a bullish trend with support at $426 and resistance at $434. Recent acquisitions in data center and utility markets position ETN for durable growth in key infrastructure sectors.
Outlook remains positive with a $502.38 consensus price target representing 16% upside. Key opportunities include data center demand and grid modernization, while risks involve execution of recent acquisitions and potential market volatility. The company's strong backlog and strategic positioning in high-growth infrastructure markets support continued investor confidence.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
